Dermatol. praxi. 2022;16(3):130-134 | DOI: 10.36290/der.2022.025

Treatment of spinalioma in clinical practice

MUDr. Ondřej Kodet
Dermatovenerologická klinika 1. LF UK a VFN, Praha
Anatomický ústav 1. LF UK, Praha
BIOCEV - Biotechnologické a biomedicínské centrum Akademie věd a Univerzity Karlovy ve Vestci u Prahy

Cutaneous squamous cell carcinoma (spinalioma) is one of the most common cancers. Its incidence is constantly increasing and thus represents a significant health socio-economic problem. The basic of treatment is radical surgical excision with a sufficient margin of healthy tissue, of the non-surgical options, the method of choice is radiotherapy. The introduction of immunotherapy into the treatment of metastatic and locally advanced cutaneous spinalioma brought significant improvements in the care of these patients, was essential. The dermatologist struggles with the diagnosis of spinalioma in current clinical practice, and its necessary to control of the basic possibilities of treatment.

Keywords: spinalioma, radical excision, radiotherapy, immunotherapy, cemiplimab.

Accepted: October 11, 2022; Published: October 17, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kodet O. Treatment of spinalioma in clinical practice. Dermatol. praxi. 2022;16(3):130-134. doi: 10.36290/der.2022.025.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Rogers HW, Weinstock MA, Feldman SR, Coldiron BM. Incidence Estimate of Nonmelanoma Skin Cancer (Keratinocyte Carcinomas) in the U.S. Population, 2012. JAMA dermatology [Internet]. 2015 Oct 1 [cited 2022 May 16];151(10):1081-1086. Available from: https://pubmed.ncbi.nlm.nih.gov/25928283/. Go to original source... Go to PubMed...
    2. Brougham NDL, Tan ST. The incidence and risk factors of metastasis for cutaneous squamous cell carcinoma--implications on the T-classification system. J Surg Oncol [Internet]. 2014 Dec 1 [cited 2022 May 16];110(7):876-882. Available from: https://pubmed.ncbi.nlm.nih.gov/25088537/. Go to original source... Go to PubMed...
    3. Leiter U, Keim U, Eigentler T, Katalinic A, Holleczek B, Martus P, et al. Incidence, Mortality, and Trends of Nonmelanoma Skin Cancer in Germany. J Invest Dermatol [Internet]. 2017 Sep 1 [cited 2022 May 16];137(9):1860-1867. Available from: https://pubmed.ncbi.nlm.nih.gov/28487088/. Go to original source... Go to PubMed...
    4. Brash DE, Rudolph JA, Simon JA, Lin A, Mckenna GJ, Baden HP, et al. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci U S A [Internet]. 1991 [cited 2022 May 16];88(22):10124-10128. Available from: https://pubmed.ncbi.nlm.nih.gov/1946433/ Go to original source... Go to PubMed...
    5. Schmults CD, Karia PS, Carter JB, Han J, Qureshi AA. Factors predictive of recurrence and death from cutaneous squamous cell carcinoma: a 10-year, single-institution cohort study. JAMA dermatology [Internet]. 2013 May [cited 2022 May 16];149(5):541-547. Available from: https://pubmed.ncbi.nlm.nih.gov/23677079/. Go to original source... Go to PubMed...
    6. Alam M, Armstrong A, Baum C, Bordeaux JS, Brown M, Busam KJ, et al. Guidelines of care for the management of cutaneous squamous cell carcinoma. J Am Acad Dermatol [Internet]. 2018 Mar 1 [cited 2022 May 16];78(3):560-578. Available from: https://pubmed.ncbi.nlm.nih.gov/29331386/. Go to original source... Go to PubMed...
    7. Lansbury L, Bath-Hextall F, Perkins W, Stanton W, Leonardi-Bee J. Interventions for non-metastatic squamous cell carcinoma of the skin: systematic review and pooled analysis of observational studies. BMJ [Internet]. 2013 [cited 2022 May 16];347. Available from: https://pubmed.ncbi.nlm.nih.gov/24191270/. Go to original source...
    8. Thompson AK, Kelley BF, Prokop LJ, Murad MH, Baum CL. Risk Factors for Cutaneous Squamous Cell Carcinoma Recurrence, Metastasis, and Disease-Specific Death: A Systematic Review and Meta-analysis. JAMA dermatology [Internet]. 2016 Apr 1 [cited 2022 May 16];152(4):419-428. Available from: https://pubmed.ncbi.nlm.nih.gov/26762219/. Go to original source... Go to PubMed...
    9. Westers-Attema A, Joosten VMHJ, Roozeboom MH, Nelemans PJ, Lohman BGPM, Botterweck AA, et al. Correlation between histological findings on punch biopsy specimens and subsequent excision specimens in cutaneous squamous cell carcinoma. Acta Derm Venereol [Internet]. 2015 [cited 2022 May 16];95(2):181-185. Available from: https://pubmed.ncbi.nlm.nih.gov/24556935/. Go to original source... Go to PubMed...
    10. Chren MM, Sahay AP, Bertenthal DS, Sen S, Landefeld CS. Quality-of-life outcomes of treatments for cutaneous basal cell carcinoma and squamous cell carcinoma. J Invest Dermatol [Internet]. 2007 Jun [cited 2022 May 16];127(6):1351-1357. Available from: https://pubmed.ncbi.nlm.nih.gov/17301830/. Go to original source... Go to PubMed...
    11. Brodland DG, Zitelli JA. Surgical margins for excision of primary cutaneous squamous cell carcinoma. J Am Acad Dermatol [Internet]. 1992 [cited 2022 May 16];27(2 Pt 1):241-248. Available from: https://pubmed.ncbi.nlm.nih.gov/1430364/. Go to original source... Go to PubMed...
    12. Rowe DE, Carroll RJ, Day CL. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. J Am Acad Dermatol [Internet]. 1992 [cited 2022 May 16];26(6):976-990. Available from: https://pubmed.ncbi.nlm.nih.gov/1607418/. Go to original source... Go to PubMed...
    13. Carter JB, Johnson MM, Chua TL, Karia PS, Schmults CD. Outcomes of primary cutaneous squamous cell carcinoma with perineural invasion: an 11-year cohort study. JAMA dermatology [Internet]. 2013 Jan [cited 2022 May 16];149(1):35-42. Available from: https://pubmed.ncbi.nlm.nih.gov/23324754/. Go to original source... Go to PubMed...
    14. Van Loo E, Mosterd K, Krekels GAM, Roozeboom MH, Ostertag JU, Dirksen CD, et al. Surgical excision versus Mohs' micrographic surgery for basal cell carcinoma of the face: A randomised clinical trial with 10 year follow-up. Eur J Cancer [Internet]. 2014 [cited 2022 May 16];50(17):3011-3020. Available from: https://pubmed.ncbi.nlm.nih.gov/25262378/. Go to original source... Go to PubMed...
    15. Connolly SM, Baker DR, Coldiron BM, Fazio MJ, Storrs PA, Vidimos AT, et al. AAD/ACMS/ASDSA/ASMS 2012 appropriate use criteria for Mohs micrographic surgery: a report of the American Academy of Dermatology, American College of Mohs Surgery, American Society for Dermatologic Surgery Association, and the American Society for Mohs Surgery. J Am Acad Dermatol [Internet]. 2012 [cited 2022 May 16];67(4):531-550. Available from: https://pubmed.ncbi.nlm.nih.gov/22959232/. Go to original source... Go to PubMed...
    16. Mendenhall WM, Amdur RJ, Hinerman RW, Cognetta AB, Mendenhall NP. Radiotherapy for cutaneous squamous and basal cell carcinomas of the head and neck. Laryngoscope [Internet]. 2009 Oct [cited 2022 May 16];119(10):1994-1999. Available from: https://pubmed.ncbi.nlm.nih.gov/19688856/. Go to original source... Go to PubMed...
    17. Muto P, Pastore F. Radiotherapy in the Adjuvant and Advanced Setting of CSCC. Dermatol Pract Concept [Internet]. 2021 [cited 2022 May 16];11(Suppl 2). Available from: https://pubmed.ncbi.nlm.nih.gov/34877076/. Go to original source... Go to PubMed...
    18. Wang H, Xu Y, Shi J, Gao X, Geng L. Photodynamic therapy in the treatment of basal cell carcinoma: a systematic review and meta-analysis. Photodermatol Photoimmunol Photomed [Internet]. 2015 Jan 1 [cited 2022 May 16];31(1):44-53. Available from: https://pubmed.ncbi.nlm.nih.gov/25377432/. Go to original source... Go to PubMed...
    19. Rhodes LE, De Rie MA, Leifsdottir R, Yu RC, Bachmann I, Goulden V, et al. Five-year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. Arch Dermatol [Internet]. 2007 Sep [cited 2022 May 16];143(9):1131-1136. Available from: https://pubmed.ncbi.nlm.nih.gov/17875873/. Go to original source... Go to PubMed...
    20. Další literatura u autora a na www.dermatologiepropraxi.czCengiz FP, Kelahmetoglu O, Emiroglu N, Onsun N. Imiquimod 5% Cream as Adjuvant Therapy in BCC Treatment Located at High-Risk Regions. J Cutan Med Surg [Internet]. 2020 Nov 1 [cited 2022 May 16];24(6):640-641. Available from: https://pubmed.ncbi.nlm.nih.gov/32558591/.
    21. Tiodorovic-Zivkovic D, Zalaudek I, Longo C, De Pace B, Albertini G, Argenziano G. Successful treatment of two invasive squamous cell carcinomas with topical 5% imiquimod cream in elderly patients. Eur J Dermatol [Internet]. 2012 [cited 2022 May 16];22(4):579-580. Available from: https://pubmed.ncbi.nlm.nih.gov/22652500/. Go to original source... Go to PubMed...
    22. Peris K, Piccerillo A, Del Regno L, Di Stefani A. Treatment approaches of advanced cutaneous squamous cell carcinoma. J Eur Acad Dermatol Venereol [Internet]. 2022 Jan 1 [cited 2022 May 16];36 Suppl 1(S1):19-22. Available from: https://pubmed.ncbi.nlm.nih.gov/34855254/. Go to original source... Go to PubMed...
    23. Alberti A, Bossi P. Immunotherapy for Cutaneous Squamous Cell Carcinoma: Results and Perspectives. Front Oncol [Internet]. 2022 Jan 5 [cited 2022 May 16];11. Available from: https://pubmed.ncbi.nlm.nih.gov/35070956/. Go to original source... Go to PubMed...
    24. Ahmed SR, Petersen E, Patel R, Migden MR. Cemiplimab-rwlc as first and only treatment for advanced cutaneous squamous cell carcinoma. Expert Rev Clin Pharmacol [Internet]. 2019 Oct 3 [cited 2022 May 16];12(10):947-951. Available from: https://pubmed.ncbi.nlm.nih.gov/31524530/. Go to original source... Go to PubMed...
    25. Rischin D, Migden MR, Lim AM, Schmults CD, Khushalani NI, Hughes BGM, et al. Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing. J Immunother cancer [Internet]. 2020 Jun 17 [cited 2022 May 16];8(1). Available from: https://pubmed.ncbi.nlm.nih.gov/32554615/. Go to original source... Go to PubMed...
    26. Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD, et al. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. N Engl J Med [Internet]. 2018 Jun 4 [cited 2022 May 16];379(4). Available from: https://pubmed.ncbi.nlm.nih.gov/29863979/. Go to original source... Go to PubMed...

    Return to the content


    Dermatology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.